CTI BioPharma Corp., a company that specializes in developing blood cancer treatments, has named Michael Metzger its new director.
“We are pleased to welcome Michael to the board of directors, “ Richard Love, CTI's interim president and CEO, said. “Michael is an accomplished leader and builder of biotech companies, and his track record of success in creating value for shareholders through business development and strategic financial transactions will be a valuable resource for us as our programs continue to progress.”
Most recently CEO of Syndax Pharmaceuticals, Metzger also has served as CEO for Regado Biosciences, Tobira Therapeutics and Mersana Therapeutics.
“I look forward to working with the board and management of CTI to help the company reach the next level of success as it develops and commercializes innovative therapeutics,” Metzger said. “CTI is at a transformation point with an opportunity to address an important unmet need in myelofibrosis with pacritinib and I am excited to join their efforts.”